Genaera Corp.

Genaera Corp.

• Squalamine lactate is being evaluated in a Phase 2 Clinical Study (Study 204), as a therapy for the treatment of prostate cancer.
• LOMUCIN™ is being evaluated in a Phase 2 Clinical Study (Study 203), as a therapy for the treatment of cystic fibrosis.
• MSI-1436 is a development candidate for the treatment of obesity. Genaera plans to conduct first-in-man clinical studies in 1H07.
• Anti-IL9 is being evaluated for safety by MedImmune (Genaera’s licensee) in Phase 1 clinical studies. Please refer to www.medimmune.com for status of this program.

(GENR :

 

GENR0.34, +0.04, +13.3% ) shares plunged 35% after the company said it plans to terminate the Evizon clinical development program in wet age-related macular degeneration and cut its workforce by roughly 30%. The Plymouth Meeting, Pa.-based biopharmaceutical company said it will instead focus its resources on the development of trodusquemine for the treatment of obesity. Genaera added that it has engaged Banc of America Securities LLC as its financial advisor to assist the company in its review of strategic alternatives.

GENR – GENAERA CORP (NASDAQd)

Date	Open	High	Low	Last	Change	Volume	% Change
02/12/07	0.30	0.35	0.30	0.34	+0.04	3123300	+13.33 %

02/09/07	0.27	0.31	0.27	0.30	+0.03	1661500	+11.11 %
02/08/07	0.26	0.27	0.25	0.27	+0.02	269200	+8.00 %
02/07/07	0.25	0.27	0.25	0.25	unch	896600	unch %
02/06/07	0.26	0.26	0.25	0.25	unch	739200	unch %

— Period —	— High —		— Low —
5-Day	0.35	on 02/12/07	0.25	on 02/06/07
20-Day	0.35	on 02/12/07	0.22	on 01/22/07
65-Day	0.43	on 11/14/06	0.22	on 01/22/07
100-Day	0.45	on 10/16/06	0.22	on 01/22/07
260-Day	1.80	on 02/24/06	0.22	on 01/22/07
Year to Date	0.41	on 01/03/07	0.22	on 01/22/07

For The Last	Made New High	Percent From	Made New Low	Percent From
5 days	4 time(s)	-2.86 %	1 time(s)	+36.00 %
20 days	4 time(s)	-2.86 %	4 time(s)	+54.55 %
65 days	1 time(s)	-20.93 %	10 time(s)	+54.55 %
100 days	3 time(s)	-24.44 %	6 time(s)	+54.55 %
260 days	6 time(s)	-81.11 %	29 time(s)	+54.55 %
Year to Date	1 time(s)	-17.07 %	5 time(s)	+54.55 %